Amylyx Pharmaceuticals, Inc.
AMLXAmylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
AMLX Earnings Report
EPS Est: $-0.36 | FQ end 2026-06 | Call: 2026-08-06 07:00:00
How AMLX's past catalysts played out
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Amylyx Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Amylyx Pharmaceuticals, Inc.'s (AMLX) pipeline across Phase 3. Its lead program is AMX0035 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amylyx Pharmaceuticals, Inc.'s next FDA catalyst?→
Amylyx Pharmaceuticals, Inc.'s (AMLX) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AMLX biotech catalysts?→
Add AMLX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amylyx Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.